SYLQDSVPDSFQD, anchor-modified for high-affinity binding to DR4, is a DR4-restricted MHC class II peptide Tyrosinase[1].
References
[1] Schadendorf D, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006 Apr;17(4):563-70. DOI:10.1093/annonc/mdj138
